MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-1020-3

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2004

Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.

Mulshine James L, Atkinson Jane C, Greer Robert O, Papadimitrakopoulou Vassiliki A, Van Waes Carter, Rudy Susan, Martin Jack W, Steinberg Seth M, Liewehr David J, Avis Ingalill, Linnoila R Ilona, Hewitt Stephen, Lippman Scott M, Frye Robin, Cavanaugh Paul F

Клиническое исследованиеКлиническое исследование II фазыСтатьяРандомизированное исследованиеПоддержка службы здравоохранения СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Nonselective cyclooxygenase (COX) inhibitors have been reported to decrease the frequency of upper aerodigestive cancers. Ketorolac tromethamine oral rinse has been shown to resolve another COX-dependent process, periodontal disease, without incurring gastrointestinal side effects. This trial evaluated if a topically delivered oral rinse containing ketorolac was as safe as and more effective than oral rinse alone in reducing the area of oral leukoplakia.

EXPERIMENTAL

DESIGN

57 patients were randomized (2:1 ratio) in a double-blind, placebo-controlled study of ketorolac (10 ml of a 0.1% ketorolac rinse solution; n = 38) or placebo (10 ml of rinse solution; n = 19) given twice daily for 30 s over 90 days. Primary end point was evaluated visually obtaining bidimensional measurement of the size of leukoplakia lesion(s) at entry and at 90 days. Secondary end point was histological assessment of the leukoplakia as sampled by serial punch biopsy and independently reviewed by three pathologists.

RESULTS

The patients included 67% males, 11% non-Caucasian, and 86% used tobacco with no significant differences between the two arms. Both rinses were well tolerated with good compliance, and there was no significant difference in adverse events (P = 0.27). Major response rate (complete response and partial response) was 30% for ketorolac and 32% for the placebo arm. There was no significant difference in change in histology between the two arms.

CONCLUSION

Local delivery of a COX-containing oral rinse was well tolerated but produced no significant reduction in the extent of leukoplakia compared with the placebo. However, the favorable response rate to placebo arm remains unexplained and additional investigation of the tissue penetration with ketorolac is warranted.

Для цитирования: Mulshine James L, Atkinson Jane C, Greer Robert O, Papadimitrakopoulou Vassiliki A, Van Waes Carter, Rudy Susan, Martin Jack W, Steinberg Seth M, Liewehr David J, Avis Ingalill, Linnoila R Ilona, Hewitt Stephen, Lippman Scott M, Frye Robin, Cavanaugh Paul F. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. DOI: 10.1158/1078-0432.ccr-1020-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.